1.
|
11 p, 3.4 MB |
PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
/
Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ;
Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ;
Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ;
Boland, Genevieve (Massachusetts General Hospital (Boston)) ;
Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ;
Lewis, Karl D. (University of Colorado Cancer Center) ;
Johnson, Daniel (Ochsner Medical Center) ;
Rivalland, Gareth (University of Auckland & Auckland City Hospital) ;
Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Gogas, Helen (National & Kapodistrian University of Athens) ;
Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ;
Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ;
Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913
|
|
3.
|
20 p, 2.2 MB |
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
/
Corominas Argente del Castillo, Josep (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Sapena, Victor (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Sanduzzi Zamparelli, Marco (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Millán, Cristina (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Samper, Esther (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Llarch, Neus (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Iserte, Gemma (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Torres, Ferran (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Da Fonseca, Leonardo G. (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Muñoz-Martínez, S (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Forner, Alejandro (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Bruix, Jordi (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Boix, Loreto (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ;
Reig, María (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. [...]
2021 - 10.3390/cancers13030426
Cancers, Vol. 13 (january 2021)
|
|
4.
|
14 p, 3.2 MB |
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 + T Cells and Evolve at the Population Level
/
Karimzadeh, Hadi (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Kiraithe, Muthamia M. (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Oberhardt, Valerie (Faculty of Biology, University of Freiburg, Freiburg, Germany) ;
Salimi Alizei, Elahe (Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany) ;
Bockmann, Jan (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Schulze zur Wiesch, Julian (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Budeus, Bettina (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Hoffmann, Daniel (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Wedemeyer, Heiner (University Hospital Essen (Alemanya)) ;
Cornberg, Markus (Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany) ;
Krawczyk, Adalbert (Department of Infectious Diseases, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany) ;
Rashidi-Alavijeh, Jassin (University Hospital Essen (Alemanya)) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Casillas, Rosario (Hospital Universitari Vall d'Hebron) ;
Buti, Maria (Hospital Universitari Vall d'Hebron) ;
Smedile, Antonina (Department of Medical Sciences, University of Turin, Turin, Italy) ;
Alavian, Seyed Moayed (Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran) ;
Heinold, Andreas (University Hospital Essen (Alemanya)) ;
Emmerich, Florian (Institute for Transfusion Medicine and Gene Therapy, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Panning, Marcus (Institute of Virology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Gostick, Emma (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Price, David A. (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Timm, Jörg (Institute of Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany) ;
Hofmann, Maike (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Raziorrouh, Bijan (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Thimme, Robert (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Protzer, Ulrike (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Roggendorf, Michael (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Neumann-Haefelin, Christoph (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Universitat Autònoma de Barcelona
Hepatitis D virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma. Treatment options are limited, and no vaccine is available. [...]
2019 - 10.1053/j.gastro.2019.02.003
Gastroenterology, Vol. 156 (may 2019) , p. 1820-1833
|
|